LV Intermectin 10 mg/ml šķīdums injekcijām 라트비아 - 라트비아어 - Pārtikas un veterinārais dienests, Zemkopības ministrija

lv intermectin 10 mg/ml šķīdums injekcijām

interchemie werken de adelaar eesti as, igaunija - ivermektīns - šķīdums injekcijām - 10 mg/ml - aitas; cūkas; kazas; liellopi

Prothromplex Total 600 SV pulveris un šķīdinātājs injekciju šķīduma pagatavošanai 라트비아 - 라트비아어 - Zāļu valsts aģentūra

prothromplex total 600 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai

baxalta innovations gmbh, austria - protrombīna komplekss, cilvēka - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 600 sv

Trecondi 유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

trecondi

medac gesellschaft für klinische spezialpräparate mbh - treosulfāns - hematopoētiskā cilmes šūnu transplantācija - antineoplastiski līdzekļi - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

Scemblix 유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - leikēmija, mielogēns, hronisks, bcr-abl pozitīvs - antineoplastiski līdzekļi - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Imatinib Accord 유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

imatinib accord

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. izņemot tikko diagnosticēta cml hroniskā fāzē, nav kontrolētos pētījumos, kas liecina par klīnisko ieguvumu vai palielina izdzīvošanas šo slimību. .

Alfatrim 24% šķīdums injekcijām 라트비아 - 라트비아어 - Pārtikas un veterinārais dienests, Zemkopības ministrija

alfatrim 24% šķīdums injekcijām

alfasan international b.v., nīderlande - trimethoprim, sulfametoxasole - šķīdums injekcijām - cūkas; kaķi; liellopi; suņi